Optimized Treatment Schedules for Chronic Myeloid Leukemia

Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations tha...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qie, Zhu, Junfeng, Dingli, David, Foo, Jasmine, Leder, Kevin Zox
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072565/
https://www.ncbi.nlm.nih.gov/pubmed/27764087
http://dx.doi.org/10.1371/journal.pcbi.1005129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072565/
https://www.ncbi.nlm.nih.gov/pubmed/27764087
http://dx.doi.org/10.1371/journal.pcbi.1005129

Ejemplares similares